BioNTech initiated with a Buy at Truist
Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it ...
Promising Oncology Pipeline and Financial Strength Drive BioNTech’s Growth Prospects
Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...
Richmond Free Press12h
Free community testing for COVID-19 continues
For the week ending Saturday, Jan. 4, COVID-19 accounted for 1.6% of all emergency department visits in Virginia, with ...
mRNA Cancer Vaccines Clinical Trials Ongoing Research Development Insight
First Commercial mRNA Vaccine Approval Expected By 2029 Says Kuick ResearchDelhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Global ...